Treatment study for p53 mutant oral cancer and precancers
Part of Cancer clinical trials.
This trial tests different treatments for people with oral cancer or precancerous lesions that have a p53 mutation. It aims to find the best approach for early-stage disease to prevent progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have never had radiation to the head or neck.
- Your biopsy shows a p53 mutation (detected by a special stain).
- You are not immunocompromised.
- Your lesion is 3 cm or smaller and not a type called proliferative verrucous leukoplakia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at two tumor test results—HPV and p53—to help doctors decide how much tissue to remove during surgery for vulvar squamous cell carcinoma. It’s meant to reduce the risk of the cancer coming back while avoiding unnecessary removal when margins are only close.
This Phase 2 trial tests a chemotherapy plan given first (before surgery) for people with oral squamous cell carcinoma that has specific cancer markers and lymph node involvement. It aims to shrink or control the cancer so treatment after may work better.
This research study examines how oral cancer develops by collecting tissue samples from people with oral cancer or pre-cancerous mouth conditions. The goal is to understand what changes happen in the mouth that lead to cancer, which may help improve diagnosis and treatment in the future.
This trial tests whether giving a type of radiation therapy (proton or photon) along with the immunotherapy drug pembrolizumab before surgery is safe and effective for people with certain oral cavity cancers. The goal is to see if this combination can shrink the tumor and improve outcomes.
This Phase 2 study tests medicines given before surgery for stage III/IV oral squamous cell carcinoma, choosing the treatment based on your tumor marker results. It aims to shrink the cancer and improve outcomes by using two targeted types of therapy.
This trial tests whether PRV111, PRV211, and PRV131 are safe and work better than expected for certain mouth (lip/oral cavity) cancers and lung cancers. It may help by trying a new approach given directly to the tumor and then monitoring how well it shrinks and how safe it is.
Hear when a new Oral Epithelial Dysplasia (OED) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.